Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Catar...
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
Proportion of Patients Requiring Rescue Sedation Was Nearly Two-Fold Higher for Sublingual Midazolam Compared with MELT-300 (P=0.003) MELT-300 Had a Favorable Safety Profile That Was Generally Comparable to Placebo NASHVILLE, Tenn., November 20, 2024 BUSINESS WIRE )--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration ("FDA") earlier this year, this study design and these positive results support the necessary objectives required for a regulatory submission. MELT-300 uniquely combines a fixed dose of midazolam (3mg) and ketamine (50mg) in one tablet that is administered sublingually u
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND) [Yahoo! Finance]Yahoo! Finance
- Matica Biotechnology Appoints Life Sciences Leader Min Park, MBA to Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Pharmaceutical Outsourcing Launches New Clinical Trials Documentary: Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs [Yahoo! Finance]Yahoo! Finance
- OpenText World 2024 Unites Industry Leaders to Tackle AI and Information Management [Yahoo! Finance]Yahoo! Finance
- High Potency API Contract Manufacturing Market Forecast, 2025-2030 - Rising Demand for Oncology Drugs and Advancements in Manufacturing Technology Driving the Industry at 10.98% CAGR [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- CTLT's page on the SEC website